Skip to content

Clinicopathological Value of p16 Expression in Colorectal Carcinoma

Clinicopathological Value of p16 Expression in Colorectal Carcinoma: An Immunohistochemical Study.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07047482
Enrollment
50
Registered
2025-07-02
Start date
2025-05-01
Completion date
2026-12-30
Last updated
2025-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Carcinoma

Keywords

p16 Expression, Colorectal Carcinoma, Immunohistochemical study

Brief summary

Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.

Detailed description

Colorectal Carcinoma is very common nowadays, with increasing need for further research. p16 is tumor suppressor gene with a vital rule ; inactivation of p16 leads to tumor formation and progression. 50 Specimens will be collected from Pathology Department of Sohag University Hospital. Sufficient clinical and histopathological data will be attached for each case. The previously processed formalin-fixed, paraffin-embedded tissue blocks will be used to get Hematoxylin & Eosin stained sections to confirm the diagnosis and to detect the histopathological type, grade and stage of each tumor. Another sliced tissue sections will be immunohistochemically stained with p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.

Interventions

Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Specimens from patients with colorectal cancer. 2. Tissue blocks with sufficient material. 3. Specimens with sufficient clinical data.

Exclusion criteria

1. Tissue blocks with insufficient, destroyed or necrotic material. 2. Specimens with insufficient clinical data.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of p16 Expression in Colorectal Carcinoma.6 monthsImmunohistochemical staining of Colorectal tissues by p16 monoclonal antibody

Secondary

MeasureTime frameDescription
Correlation of p16 expression to different clinical and pathological parameters6 monthsCorrelation of p16 expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.

Countries

Egypt

Contacts

Primary ContactSherry R Azmy, Demonstrator of pathology
shery.raoof@med.sohag.edu.eg01507557371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026